Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy

Experimental and Molecular Medicine

Volumn 41, Issue 11, 2009, Pages 802-811

  Yoon, Se Jung ^a   Yoon, Young Won ^b   Lee, Byoung Kwon ^b   Kwon, Hyuck Moon ^b   Hwang, Ki Chul ^c   Kim, Myunghyun ^b   Chang, Woochul ^c   Hong, Bum Kee ^b   Lee, Young Ho ^c   Park, Soon Jung ^c   Min, Pil Ki ^b   Rim, Se Joong ^b  

^a National Health Insurance Corporation   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Cyclooxygenase 2; Diabetes mellitus; Extracellular signal regulated MAP kinases; Hydroxymethylglutaryl CoA reductase inhibitors; Muscle, smooth, vascular; NF B; p38 mitogen activated protein kinases; Proto oncogene proteins c jun; Reactive oxygen species

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN C JUN; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; SMALL INTERFERING RNA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA MEDIA; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY INJURY; CELL CULTURE; CELL PROLIFERATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DIABETIC ANGIOPATHY; DRUG MECHANISM; ENZYME ACTIVATION; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RAT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STREPTOZOCIN DIABETES; TRANSCRIPTION INITIATION; UPREGULATION;

RATTUS;

EID: 73649130629     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2009.41.11.086     Document Type: Article

References (35)

1. Arumugam T, Simeone DM, Golen KV, Logsdon CD. S100P Promotes Pancreatic Cancer Growth, Survival, and Invasion. Clin Cancer Res 2005;11:5356-64
2. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for advanced glycation end products RAGE. J Biol Chem 2004;279:5059-65
3. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999;48:1-9
4. Bierhaus A, Chevion S, Chevion M, Hofmann M, Quehenberger P, Illmer T, Luther T, Berentshtein E, Tritschler H, Mu?ller M, Wahl P, Ziegler R, Nawroth PP. Advanced glycation endproduct-induced activation of NFκB is suppressed by alpha-lipooic acid in cultured endothelial cells. Diabetes 1997;46:1481-90
5. Brown MR, Miller FJ Jr, Li WG, Ellingson AN, Mozena JD, Chatterjee P, Engelhardt JF, Zwacka RM, Oberley LW, Fang X, Spector AA, Weintraub NL. Overexpression of human catalase inhibits proliferation and promotes apoptosis in vascular smooth muscle cells. Circ Res 1999;85:524-33
6. Brownlee M, Cerami A, Vlassara H. Advanced glycation end product in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-23
7. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002;105:1816-23
8. Chen Z, Fukutomi T, Zago AC, Ehlers R, Detmers PA, Wright SD, Rogers C, Simon DI. Simvastatin Reduces Neointimal Thickening in Low-Density Lipoprotein Receptor-Deficient Mice After Experimental Angioplasty Without Changing Plasma Lipids. Circulation 2002;106:20-3
9. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003;108:1070-7
10. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, Bei R, Ucchino S, Spigonardo F, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A, Cipollone F. Suppression of Rage as a Basis of Simvastatin-Dependent Plaque Stabilization in Type 2 Diabetes. Arterioscler Thromb Vasc Biol 2006;26:2716-23
11. Davignon J. Beneficial Cardiovascular Pleiotropic Effects of Statins. Circulation 2004;109(suppl III):III-39-III-43
12. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993;1165:335-8
13. Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells. Circulation 2004;110:851-61
14. Hong BK, Kwon HM, Lee BK, Kim D, Kim IJ, Kang SM, Jang Y, Cho SH, Kim HK, Jang BC, Cho SY, Kim HS, Kim MS, Kwon HC, Lee N. Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J 2000;41:82-8
15. Jones SP, Trocha SD, Lefer DJ. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Circulation 2001;21:2059-64
16. Kanauchi M, Hashimoto T, Tsujimoto N. Advanced Glycation End Products in Nondiabetic Patients With Coronary Artery Disease. Diabetes Care 2001;24:1620-3
17. Kim SE, Thanh Thuy TT, Lee JH, Ro JY, Bae YA, Kong Y, Ahn JY, Lee DS, Oh YM, Lee SD, Lee YS. Simvastatin inhibits induction of matrix metalloproteinase-9 in rat alveolar macrophages exposed to cigarette smoke extract. Exp Mol Med 2009;41:277-87
18. Komukai M, Wajima YS, Tashiro J, Shinomiya M, Saito Y, Morisaki N. Carvastatin suppresses intimal thickening of rabbit carotid artery after balloon catheter injury probably through the inhibition of vascular smooth muscle cell proliferation and migration. Scand J Clin Lab Invest 1999;59:159-66
19. Kornowski R, Mintz GS, Kent KM, Pichard AD, Satler LF, Bucher TA, Hong MK, Popma JJ, Leon MB. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997;95:1366-9
20. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int 1999;71(Suppl):S2-S5
21. Park SH, Marso SP, Zhou Z, Foroudi F, Topol EJ, Lincoff AM. Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation 2001;104:815-9
22. Pontsler AV, St Hilaire A, Marathe GK, Zimmerman GA, McIntyre TM. Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein. J Biol Chem 2002;277:13029-36
23. Rauvala H, Huttunen HJ, Fages C, Kaksonen M, Kinnunen T, Imai S, Raulo E, Kilpeläinen I. Heparin-binding proteins HB-GAM (pleiotrophin) and amphoterin in the regulation of cell motility. Matrix Biol 2000;19:377-87
24. Rojas A, Morales MA. Advanced glycation and endothelial functions: A link towards vascular complications in diabetes. Life Sciences 2004;76:715-30
25. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM, Schmidt AM, Naka Y. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003;111:959-72
26. Schonbeck U, Sukhova G, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999;155:1281-91
27. Senokuchi T, Matsumura T, Sakai M, Yano M, Taguchi T, Matsuo T, Sonoda K, Kukidome D, Imoto K, Nishikawa T, Kim-Mitsuyama S, Takuwa Y, Araki E. Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein-p38 MAPK pathway. J biol. chem. 2005;280:6627-33
28. Shanmugam N, Kim YS, Lanting L, Natarajan R. Regulation of Cyclooxygenase-2 Expression in Monocytes by Ligation of the Receptor for Advanced Glycation End Products. J Biol Chem 2003;278:34834-44
29. Singh R, Singh N, Rastogi S. Antioxidants effects of lovastatin and vitamin E on experimental atherosclerosis in rabbits. Cardiovasc Drugs Ther 1997;11:575-80
30. Stephenson K, Tunstead J, Tsai A, Gordon R, Henderson S, Dansky HM. Neointimal formation after endovascular arterial injury is markedly attenuated in db/db mice. Arterioscler Thromb Vasc Biol 2003;23:2027-33
31. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-60
32. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9
33. Takemoto M, Node K, Hironori N. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001;108:1429-37
34. Wassmann S, Laufs U, Müller K, Konkol C, Ahlbory K, Bäumer AT, Linz W, Böhm M, Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002;22:300-5
35. Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Forudi F, Zhou X, Qu W, Lu Y, Stern DM, Schmidt AM, Lincoff AM, Topol EJ. Receptor for AGEs (RAGE) mediates neointimal formation in response to arterial injury. Circulation 2003;107:2238-43